LPX Lipoxen

 

TIDMLPX 
 
RNS Number : 7399K 
Lipoxen PLC 
26 April 2010 
 

+---------------------------------+---------------------------------+ 
| For immediate release           |                   26 April 2010 | 
+---------------------------------+---------------------------------+ 
 
 
                                  Lipoxen PLC 
                          ('Lipoxen' or 'the Company') 
 
                                DIRECTOR DEALING 
 
Lipoxen PLC (AIM: LPX), a bio-pharmaceutical company specialising in the 
development of high-value differentiated biologicals, vaccines and siRNA 
delivery, has been informed that certain directors have acquired ordinary shares 
of 0.5 pence each (the "New Ordinary Shares"). Details of the director dealings 
are set out in the table below: 
 
+-------------+----------+---------+----------+-----------+----------+ 
| Name        |    Date  |   Price |   Shares |     Total |     % of | 
|             |          |         | acquired |  interest |    total | 
|             |          |         |          |           |   issued | 
|             |          |         |          |           |    share | 
|             |          |         |          |           |  capital | 
+-------------+----------+---------+----------+-----------+----------+ 
| Scott       | 23 April |   6.95p |  100,000 | 1,401,362 |     0.82 | 
| Maguire     |     2010 |         |          |           |          | 
+-------------+----------+---------+----------+-----------+----------+ 
| Colin Hill  | 23 April |   6.83p |  150,000 | 1,825,420 |     1.06 | 
|             |     2010 |         |          |           |          | 
+-------------+----------+---------+----------+-----------+----------+ 
|             |          |         |          |           |          | 
+-------------+----------+---------+----------+-----------+----------+ 
 
                                    - Ends - 
 
For further information please contact: 
 
+------------------------------------------+--------------------+ 
| Lipoxen plc                              |     +44 (0)20 7389 | 
|                                          |               5015 | 
+------------------------------------------+--------------------+ 
| M. Scott Maguire, Chief Executive        |                    | 
| Officer                                  |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Singer Capital Markets (nominated        |     +44 (0)20 3205 | 
| adviser)                                 |               7500 | 
+------------------------------------------+--------------------+ 
| Jeff Keating / Claes Spång               |                    | 
+------------------------------------------+--------------------+ 
|                                          |                    | 
+------------------------------------------+--------------------+ 
| Buchanan Communications                  |     +44 (0)20 7466 | 
|                                          |               5000 | 
+------------------------------------------+--------------------+ 
| Lisa Baderoon / Catherine Breen          |                    | 
+------------------------------------------+--------------------+ 
 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 RDSFMGZDVFRGGZM 
 

Lipoxen (LSE:LPX)
Historical Stock Chart
From Dec 2024 to Jan 2025

Lipoxen (LSE:LPX)
Historical Stock Chart
From Jan 2024 to Jan 2025